Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.
2.
Glioblastoma treatment breakthrough shows promise
3.
Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?
4.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
5.
Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care
1.
The Latest Research on Wiskott Aldrich Syndrome
2.
Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer
3.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
4.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
5.
Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV
2.
Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation